Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	cysteine-type deubiquitinase activity	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	1.54e-29	114	45	18	GO:0004843
GeneOntologyMolecularFunction	deubiquitinase activity	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.78e-29	124	45	18	GO:0101005
GeneOntologyMolecularFunction	ubiquitin-like protein peptidase activity	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	5.24e-28	137	45	18	GO:0019783
GeneOntologyMolecularFunction	cysteine-type peptidase activity	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	3.00e-25	192	45	18	GO:0008234
GeneOntologyMolecularFunction	peptidase activity	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18 GGT5	5.24e-17	654	45	19	GO:0008233
GeneOntologyMolecularFunction	protein-lysine 6-oxidase activity	LOXL4 LOXL3	4.94e-05	5	45	2	GO:0004720
GeneOntologyMolecularFunction	oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor	LOXL4 LOXL3	5.84e-04	16	45	2	GO:0016641
GeneOntologyMolecularFunction	oxidoreductase activity, acting on the CH-NH2 group of donors	LOXL4 LOXL3	9.20e-04	20	45	2	GO:0016638
GeneOntologyMolecularFunction	hyaluronic acid binding	USP17L6P USP17L24	1.94e-03	29	45	2	GO:0005540
GeneOntologyMolecularFunction	glycosaminoglycan binding	SELL TENM1 USP17L6P USP17L24	3.07e-03	268	45	4	GO:0005539
GeneOntologyBiologicalProcess	protein deubiquitination	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	3.07e-29	125	44	18	GO:0016579
GeneOntologyBiologicalProcess	protein modification by small protein removal	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	4.57e-28	144	44	18	GO:0070646
GeneOntologyBiologicalProcess	protein modification by small protein conjugation or removal	USP17L7 USP17L6P USP17L3 PELI2 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 NXN USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	2.95e-15	1009	44	20	GO:0070647
GeneOntologyBiologicalProcess	post-translational protein modification	USP17L7 USP17L6P USP17L3 PELI2 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 NXN USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	9.64e-15	1074	44	20	GO:0043687
GeneOntologyBiologicalProcess	response to acidic pH	SCNN1D GPR4 SLC9A1	2.56e-05	27	44	3	GO:0010447
GeneOntologyBiologicalProcess	peptidyl-lysine oxidation	LOXL4 LOXL3	4.43e-05	5	44	2	GO:0018057
GeneOntologyBiologicalProcess	protein deubiquitination involved in ubiquitin-dependent protein catabolic process	USP17L6P USP17L24	1.24e-04	8	44	2	GO:0071947
GeneOntologyBiologicalProcess	response to pH	SCNN1D GPR4 SLC9A1	1.56e-04	49	44	3	GO:0009268
GeneOntologyBiologicalProcess	protein oxidation	LOXL4 LOXL3	3.98e-04	14	44	2	GO:0018158
GeneOntologyBiologicalProcess	cellular response to acidic pH	SCNN1D SLC9A1	4.59e-04	15	44	2	GO:0071468
GeneOntologyCellularComponent	endoplasmic reticulum membrane	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 OSBP USP17L10 USP17L19 USP17L2 USP17L12 TM6SF2 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	7.97e-12	1293	46	19	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 OSBP USP17L10 USP17L19 USP17L2 USP17L12 TM6SF2 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	8.64e-12	1299	46	19	GO:0098827
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 OSBP USP17L10 USP17L19 USP17L2 USP17L12 TM6SF2 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.25e-11	1327	46	19	GO:0042175
MousePheno	increased trophectoderm apoptosis	USP17L2 USP17L15 USP17L13	4.00e-07	8	28	3	MP:0012119
MousePheno	increased thymus weight	USP17L2 USP17L15 USP17L13	1.42e-05	24	28	3	MP:0004955
MousePheno	abnormal regulatory T cell number	SELL USP17L2 USP17L15 USP17L13	7.64e-05	115	28	4	MP:0004972
MousePheno	abnormal regulatory T cell morphology	SELL USP17L2 USP17L15 USP17L13	8.17e-05	117	28	4	MP:0004941
MousePheno	abnormal thymus weight	USP17L2 USP17L15 USP17L13	2.28e-04	60	28	3	MP:0004954
MousePheno	decreased regulatory T cell number	USP17L2 USP17L15 USP17L13	2.76e-04	64	28	3	MP:0004974
Domain	HABP4_PAI-RBP1	USP17L7 USP17L3 USP17L5 USP17L21 USP17L19 USP17L2 USP17L12 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.92e-36	16	44	14	PF04774
Domain	HABP4_PAIRBP1-bd	USP17L7 USP17L3 USP17L5 USP17L21 USP17L19 USP17L2 USP17L12 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.92e-36	16	44	14	IPR006861
Domain	USP_CS	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	3.19e-29	66	44	16	IPR018200
Domain	UCH	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.19e-28	71	44	16	PF00443
Domain	USP_2	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.19e-28	71	44	16	PS00973
Domain	USP_3	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.52e-28	72	44	16	PS50235
Domain	USP_dom	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.52e-28	72	44	16	IPR028889
Domain	Peptidase_C19_UCH	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.52e-28	72	44	16	IPR001394
Domain	USP_1	USP17L7 USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L22 USP17L17 USP17L20 USP17L11 USP17L24 USP17L13 USP17L18	1.71e-26	70	44	15	PS00972
Domain	SRCR	LOXL4 LOXL3 SSC4D CD163L1	1.56e-07	21	44	4	PF00530
Domain	SR	LOXL4 LOXL3 SSC4D CD163L1	3.27e-07	25	44	4	SM00202
Domain	-	LOXL4 LOXL3 SSC4D CD163L1	3.27e-07	25	44	4	3.10.250.10
Domain	SRCR_1	LOXL4 LOXL3 SSC4D CD163L1	3.86e-07	26	44	4	PS00420
Domain	SRCR-like_dom	LOXL4 LOXL3 SSC4D CD163L1	3.86e-07	26	44	4	IPR017448
Domain	SRCR_2	LOXL4 LOXL3 SSC4D CD163L1	3.86e-07	26	44	4	PS50287
Domain	SRCR	LOXL4 LOXL3 SSC4D CD163L1	4.52e-07	27	44	4	IPR001190
Domain	Lysyl_oxidase	LOXL4 LOXL3	5.40e-05	5	44	2	IPR001695
Domain	Lysyl_oxidase_CS	LOXL4 LOXL3	5.40e-05	5	44	2	IPR019828
Domain	LYSYL_OXIDASE	LOXL4 LOXL3	5.40e-05	5	44	2	PS00926
Domain	Lysyl_oxidase	LOXL4 LOXL3	5.40e-05	5	44	2	PF01186
Domain	C_TYPE_LECTIN_1	SELL FREM1	1.53e-02	80	44	2	PS00615
Domain	Lectin_C	SELL FREM1	1.67e-02	84	44	2	PF00059
Domain	CLECT	SELL FREM1	1.67e-02	84	44	2	SM00034
Domain	C_TYPE_LECTIN_2	SELL FREM1	1.71e-02	85	44	2	PS50041
Domain	C-type_lectin-like	SELL FREM1	1.75e-02	86	44	2	IPR001304
Domain	-	SELL FREM1	2.19e-02	97	44	2	3.10.100.10
Domain	C-type_lectin-like/link	SELL FREM1	2.28e-02	99	44	2	IPR016186
Pathway	REACTOME_RAS_PROCESSING	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.67e-33	45	41	17	MM15671
Pathway	REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	9.69e-22	191	41	17	MM15289
Pathway	REACTOME_DEUBIQUITINATION	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.28e-19	262	41	17	MM15286
Pathway	REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES	USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	5.62e-19	221	41	16	M27578
Pathway	REACTOME_MAPK_FAMILY_SIGNALING_CASCADES	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	6.16e-18	318	41	17	MM15278
Pathway	REACTOME_DEUBIQUITINATION	USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.19e-17	299	41	16	M27574
Pathway	REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.07e-07	1389	41	17	MM15307
Pathway	REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION	USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 ARSD USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	2.57e-07	1475	41	17	M19806
Pathway	REACTOME_CROSSLINKING_OF_COLLAGEN_FIBRILS	LOXL4 LOXL3	1.23e-03	18	41	2	M27164
Pathway	REACTOME_CROSSLINKING_OF_COLLAGEN_FIBRILS	LOXL4 LOXL3	1.23e-03	18	41	2	MM14882
Pathway	REACTOME_COLLAGEN_FORMATION	LOXL4 LOXL3 COL26A1	1.39e-03	76	41	3	MM14573
Pathway	REACTOME_COLLAGEN_FORMATION	LOXL4 LOXL3 COL26A1	2.25e-03	90	41	3	M631
Pubmed	Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	12447969
Pubmed	DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	11468161
Pubmed	DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	18980247
Pubmed	The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	8756639
Pubmed	DUB-1, a deubiquitinating enzyme with growth-suppressing activity.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	8622927
Pubmed	DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.34e-47	21	46	17	14583620
Pubmed	JAK2 is required for induction of the murine DUB-1 gene.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.03e-46	22	46	17	9154835
Pubmed	DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.35e-45	24	46	17	8995226
Pubmed	Cdc25A and Dub3 in a high-stakes balancing act.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	3.35e-45	33	46	18	20228807
Pubmed	Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	4.21e-45	25	46	17	21115691
Pubmed	USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	19188362
Pubmed	Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	20715989
Pubmed	Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	17109758
Pubmed	Unstable transmission of the RS447 human megasatellite tandem repetitive sequence that contains the USP17 deubiquitinating enzyme gene.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	11941478
Pubmed	Human megasatellite DNA RS447: copy-number polymorphisms and interspecies conservation.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	9806828
Pubmed	The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	20368735
Pubmed	The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	15780755
Pubmed	The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	20388806
Pubmed	DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	14699124
Pubmed	The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	20403174
Pubmed	The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	10936051
Pubmed	The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	7.12e-45	34	46	18	21448158
Pubmed	Decabromodiphenyl ethane affects embryonic development by interfering with nuclear F-actin in zygotes and leads to cognitive and social disorders in offspring mice.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.22e-44	26	46	17	35816173
Pubmed	Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	1.46e-44	35	46	18	21239494
Pubmed	Cytokine-regulated protein degradation by the ubiquitination system.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	1.46e-44	35	46	18	16611142
Pubmed	The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	2.93e-44	36	46	18	20147298
Pubmed	Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	5.70e-44	37	46	18	20228808
Pubmed	Minor Splicing Factors Zrsr1 and Zrsr2 Are Essential for Early Embryo Development and 2-Cell-Like Conversion.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.02e-43	29	46	17	32527007
Pubmed	DUX is a non-essential synchronizer of zygotic genome activation.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	3.76e-38	50	46	17	31806660
Pubmed	USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 COL26A1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.02e-19	674	46	18	37196079
Pubmed	High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency.	USP17L7 USP17L6P USP17L3 USP17L2 USP17L1 USP17L15	7.97e-16	10	46	6	24207026
Pubmed	Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells.	USP17L7 USP17L6P USP17L3 USP17L2 USP17L1 USP17L15	3.50e-15	12	46	6	24695638
Pubmed	ES cell neural differentiation reveals a substantial number of novel ESTs.	USP17L7 USP17L6P USP17L3 USP17L2 USP17L1 USP17L15	1.14e-14	14	46	6	11793228
Pubmed	CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.	USP17L7 USP17L6P USP17L3 USP17L2 USP17L1 USP17L15	1.02e-13	19	46	6	28067227
Pubmed	Human and mouse proteases: a comparative genomic approach.	USP17L7 USP17L6P USP17L3 USP17L2 USP17L1 USP17L15 FREM1	1.42e-11	81	46	7	12838346
Pubmed	A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.	USP17L21 USP17L19 USP17L12 USP17L17 USP17L20 USP17L11 USP17L18	2.20e-10	119	46	7	28625976
Pubmed	Embryonic demise caused by targeted disruption of a cysteine protease Dub-2.	USP17L2 USP17L15 USP17L13	8.65e-09	4	46	3	22984479
Pubmed	Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities.	LOXL4 LOXL3	5.13e-06	3	46	2	19015874
Pubmed	Significance of the Lysyl Oxidase Members Lysyl Oxidase Like 1, 3, and 4 in Gastric Cancer.	LOXL4 LOXL3	5.13e-06	3	46	2	30045039
Pubmed	NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3.	USP17L2 NXN	5.13e-06	3	46	2	35927236
Pubmed	Structural and functional diversity of lysyl oxidase and the LOX-like proteins.	LOXL4 LOXL3	1.03e-05	4	46	2	12686136
Pubmed	Common polymorphisms in human lysyl oxidase genes are not associated with the adolescent idiopathic scoliosis phenotype.	LOXL4 LOXL3	1.71e-05	5	46	2	21740577
Pubmed	Systematic screening of lysyl oxidase-like (LOXL) family genes demonstrates that LOXL2 is a susceptibility gene to intracranial aneurysms.	LOXL4 LOXL3	2.56e-05	6	46	2	17287949
Pubmed	Novel lethal mouse mutants produced in balancer chromosome screens.	NXN FREM1	2.56e-05	6	46	2	16466971
Pubmed	DNA sequence and analysis of human chromosome 8.	USP17L7 USP17L3 USP17L1	3.59e-05	48	46	3	16421571
Pubmed	Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype.	LOXL4 LOXL3	4.77e-05	8	46	2	19458888
Pubmed	TGF-beta1 induces the different expressions of lysyl oxidases and matrix metalloproteinases in anterior cruciate ligament and medial collateral ligament fibroblasts after mechanical injury.	LOXL4 LOXL3	7.65e-05	10	46	2	23357697
Pubmed	Loss of Lysyl Oxidase-like 3 Attenuates Embryonic Lung Development in Mice.	LOXL4 LOXL3	1.78e-04	15	46	2	27645581
Pubmed	Functional genetic analysis of mouse chromosome 11.	NXN FREM1	4.25e-04	23	46	2	12955145
Interaction	FLT3 interactions	USP17L21 USP17L19 USP17L12 USP17L17 USP17L20 USP17L11 USP17L18	3.83e-06	318	42	7	int:FLT3
Interaction	USP17L2 interactions	USP17L7 USP17L2 NXN	4.00e-05	32	42	3	int:USP17L2
Interaction	USP17L7 interactions	USP17L7 USP17L2	6.33e-05	6	42	2	int:USP17L7
Cytoband	4p16.1	USP17L6P USP17L5 USP17L21 USP17L10 USP17L19 USP17L12 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	1.35e-28	79	46	14	4p16.1
Cytoband	Ensembl 112 genes in cytogenetic band chr4p16	USP17L6P USP17L5 USP17L21 USP17L10 USP17L19 USP17L12 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	5.28e-22	222	46	14	chr4p16
Cytoband	8p23.1	USP17L7 USP17L3 USP17L2 USP17L1	1.78e-05	154	46	4	8p23.1
Cytoband	Ensembl 112 genes in cytogenetic band chr8p23	USP17L7 USP17L3 USP17L2 USP17L1	9.07e-05	234	46	4	chr8p23
GeneFamily	C2-set domain containing\|Immunoglobulin like domain containing\|Scavenger receptors	SSC4D CD163L1	4.43e-04	27	21	2	1253
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	SELL FREM1	1.03e-03	41	21	2	1298
Coexpression	MADAN_DPPA4_TARGETS	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.13e-31	86	45	17	MM1312
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	1.48e-29	112	45	17	MM1095
Coexpression	GERY_CEBP_TARGETS	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	9.02e-27	160	45	17	MM1155
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 SLC9A1 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 NXN USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.95e-19	647	45	19	MM981
Coexpression	BRUINS_UVC_RESPONSE_LATE	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 LOXL3 USP17L2 MAN2C1 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	2.37e-14	1198	45	19	MM1062
Coexpression	GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 SLC9A1 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 NXN USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	3.58e-14	1226	45	19	MM979
Coexpression	MARSON_BOUND_BY_FOXP3_STIMULATED	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L13 USP17L18	8.27e-13	1072	45	17	MM1031
Coexpression	HE_LIM_SUN_FETAL_LUNG_C0_INTERM_FIBROBLAST	CA3 GGT5	1.03e-04	9	45	2	M45670
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_k-means-cluster#4_top-relative-expression-ranked_200	ANO4 PELI2 FREM1 CA3	1.86e-06	68	28	4	gudmap_developingKidney_e13.5_podocyte cells_200_k4
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_k-means-cluster#3_top-relative-expression-ranked_100	ANO4 FREM1 CA3	4.63e-06	25	28	3	gudmap_developingKidney_e13.5_podocyte cells_100_k3
CoexpressionAtlas	JC_iEC_top-relative-expression-ranked_500	ANO4 SELL TENM1 PELI2 GPR4 CD163L1	3.58e-05	490	28	6	JC_iEC_500
CoexpressionAtlas	DevelopingKidney_e15.5_Podocyte cells_emap-27915_top-relative-expression-ranked_200	ANO4 PELI2 FREM1 CA3	5.52e-05	160	28	4	gudmap_developingKidney_e15.5_Podocyte cells_200
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_200	ANO4 PELI2 FREM1 CA3	6.99e-05	170	28	4	gudmap_developingKidney_e13.5_podocyte cells_200
CoexpressionAtlas	DevelopingKidney_e13.5_podocyte cells_emap-27773_top-relative-expression-ranked_100	ANO4 FREM1 CA3	2.16e-04	89	28	3	gudmap_developingKidney_e13.5_podocyte cells_100
CoexpressionAtlas	JC_iEC_top-relative-expression-ranked_1000	ANO4 SELL TENM1 PELI2 GPR4 CD163L1 GGT5	2.18e-04	978	28	7	JC_iEC_1000
Drug	beta-carboline	LOXL4 SLC9A1 LOXL3 MAN2C1	1.92e-06	64	32	4	CID000064961
Drug	harmaline	LOXL4 SLC9A1 LOXL3	1.47e-05	34	32	3	CID000022381
Drug	5,6-dihydroxytryptamine	LOXL4 LOXL3 CA3	1.60e-05	35	32	3	CID000021163
Drug	amiguanidine	LOXL4 LOXL3	1.91e-05	5	32	2	CID000364439
Drug	5-hydroxytryptophol	LOXL4 LOXL3 GGT5	2.79e-05	42	32	3	CID000009061
Drug	1-benzyl-2-methyl-5-methoxytryptamine	LOXL4 LOXL3	2.86e-05	6	32	2	CID000009925
Drug	BU99006	LOXL4 LOXL3	2.86e-05	6	32	2	CID006603748
Drug	NSD 2023	LOXL4 LOXL3	2.86e-05	6	32	2	CID000019831
Drug	1-PCPA	LOXL4 LOXL3	2.86e-05	6	32	2	CID000194548
Drug	N-cyclopropyl-5,6-dimethoxytryptamine	LOXL4 LOXL3	2.86e-05	6	32	2	CID000156277
Drug	N-cyclopropyl-6,7-dimethoxytryptamine	LOXL4 LOXL3	2.86e-05	6	32	2	CID000156278
Drug	N-cyclopropyl-alpha-methylbenzylamine	LOXL4 LOXL3	2.86e-05	6	32	2	CID000362778
Drug	5-hydroxyisatin	LOXL4 LOXL3	2.86e-05	6	32	2	CID010352011
Drug	T 794	LOXL4 LOXL3	2.86e-05	6	32	2	CID003077680
Drug	JB 835	LOXL4 LOXL3	4.00e-05	7	32	2	CID000152988
Drug	1-benzylcyclopropylamine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000152923
Drug	dimethylphenethylamine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000025124
Drug	BU 224	LOXL4 LOXL3	4.00e-05	7	32	2	CID000002457
Drug	RS-2232	LOXL4 LOXL3	4.00e-05	7	32	2	CID000134882
Drug	M 2113	LOXL4 LOXL3	4.00e-05	7	32	2	CID000072895
Drug	N-(2-aminoethyl)benzamide	LOXL4 LOXL3	4.00e-05	7	32	2	CID000423156
Drug	SR 95191	LOXL4 LOXL3	4.00e-05	7	32	2	CID000072119
Drug	cimoxatone	LOXL4 LOXL3	4.00e-05	7	32	2	CID000052542
Drug	iproclozide	LOXL4 LOXL3	4.00e-05	7	32	2	CID000019063
Drug	brofaromine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000044570
Drug	p-dimethylaminomethylbenzylamine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000193714
Drug	tetrahydroharmine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000159809
Drug	4'-amino-MPTP	LOXL4 LOXL3	4.00e-05	7	32	2	CID000086263
Drug	4-methoxytranylcypromine	LOXL4 LOXL3	4.00e-05	7	32	2	CID003082143
Drug	1-Phenylcyclobutylamine	LOXL4 LOXL3	4.00e-05	7	32	2	CID000152214
Drug	MPTP-3-ol	LOXL4 LOXL3	4.00e-05	7	32	2	CID000100194
Drug	mofegiline	LOXL4 LOXL3	5.33e-05	8	32	2	CID006437850
Drug	AC1O5VTH	LOXL4 LOXL3	5.33e-05	8	32	2	CID006441710
Drug	pyrazidol	LOXL4 LOXL3	5.33e-05	8	32	2	CID000068802
Drug	4-fluorotranylcypromine	LOXL4 LOXL3	5.33e-05	8	32	2	CID003082666
Drug	ranbezolid	LOXL4 LOXL3	5.33e-05	8	32	2	CID000496993
Drug	2-propyl-pentylamine	LOXL4 LOXL3	5.33e-05	8	32	2	CID000170419
Drug	AC1Q6B1A	LOXL4 LOXL3	5.33e-05	8	32	2	CID000088562
Drug	4-chlorobenzylamine	LOXL4 LOXL3	5.33e-05	8	32	2	CID000066036
Drug	Q 192	LOXL4 LOXL3	5.33e-05	8	32	2	CID000077317
Drug	amezinium	LOXL4 LOXL3	5.33e-05	8	32	2	CID000071926
Drug	mebanazine	LOXL4 LOXL3	5.33e-05	8	32	2	CID000006179
Drug	amyl nitrite	SCNN1D SLC9A1 CA3	5.63e-05	53	32	3	CID000008053
Drug	metanephrine	TENM1 LOXL4 LOXL3	6.30e-05	55	32	3	CID000021100
Drug	Amiloride	SCNN1D SLC9A1	6.85e-05	9	32	2	DB00594
Drug	Lilly 51641	LOXL4 LOXL3	6.85e-05	9	32	2	CID000021485
Drug	pinoline	LOXL4 LOXL3	6.85e-05	9	32	2	CID000001868
Drug	Ro 16-6491	LOXL4 LOXL3	6.85e-05	9	32	2	CID000004289
Drug	3-amino-2-oxazolidinone	LOXL4 LOXL3	6.85e-05	9	32	2	CID000065725
Drug	toloxatone	LOXL4 LOXL3	6.85e-05	9	32	2	CID000034521
Drug	MDL 72392	LOXL4 LOXL3	6.85e-05	9	32	2	CID006439254
Drug	AC1L4KA6	LOXL4 LOXL3	6.85e-05	9	32	2	CID000158620
Drug	FLA 365	LOXL4 LOXL3	6.85e-05	9	32	2	CID000072776
Drug	AC1L1BMC	LOXL4 LOXL3	6.85e-05	9	32	2	CID000001500
Drug	FLA 336	LOXL4 LOXL3	6.85e-05	9	32	2	CID000123706
Drug	J 508	LOXL4 LOXL3	6.85e-05	9	32	2	CID000155219
Drug	RS-8359	LOXL4 LOXL3	6.85e-05	9	32	2	CID000164116
Drug	triamterene	SCNN1D SLC9A1 CA3	7.38e-05	58	32	3	CID000005546
Drug	EXP 561	LOXL4 LOXL3	8.55e-05	10	32	2	CID000027696
Drug	N-cyclopropylbenzylamine	LOXL4 LOXL3	8.55e-05	10	32	2	CID000025866
Drug	U-0521	LOXL4 LOXL3	8.55e-05	10	32	2	CID000021632
Drug	safrazine	LOXL4 LOXL3	8.55e-05	10	32	2	CID000034041
Drug	NmiQ	LOXL4 LOXL3	8.55e-05	10	32	2	CID000019850
Drug	B-003	SELL C5AR1	8.55e-05	10	32	2	CID000062691
Drug	NSC-169892	LOXL4 LOXL3	8.55e-05	10	32	2	CID000043479
Drug	acetylcadaverine	LOXL4 LOXL3	8.55e-05	10	32	2	CID000189087
Drug	Monase	LOXL4 LOXL3	8.55e-05	10	32	2	CID000008366
Drug	3-dimethylamino-1-propyne	LOXL4 LOXL3	8.55e-05	10	32	2	CID000081643
Drug	harmane	LOXL4 SLC9A1 LOXL3	9.91e-05	64	32	3	CID005281404
Drug	befloxatone	LOXL4 LOXL3	1.04e-04	11	32	2	CID000060824
Drug	4-hydroxy-3-methoxyphenylglycol-piperazine	LOXL4 LOXL3	1.04e-04	11	32	2	CID002723890
Drug	NSC55260	LOXL4 LOXL3	1.04e-04	11	32	2	CID005356351
Drug	Amiflamina	LOXL4 LOXL3	1.04e-04	11	32	2	CID000071221
Drug	GBR 12909	SCNN1D LOXL4 LOXL3	1.24e-04	69	32	3	CID000003455
Drug	DB04677	LOXL4 LOXL3 CA3	1.24e-04	69	32	3	CID005288103
Drug	FNPA	LOXL4 LOXL3	1.25e-04	12	32	2	CID000093121
Drug	anisylamine	LOXL4 LOXL3	1.25e-04	12	32	2	CID000075452
Drug	HLA20	LOXL4 LOXL3	1.25e-04	12	32	2	CID006918819
Drug	2-(2-benzofuranyl)-2-imidazoline	LOXL4 LOXL3	1.25e-04	12	32	2	CID003080926
Drug	AbeAdo	LOXL4 LOXL3	1.25e-04	12	32	2	CID006436013
Drug	tylciprine	LOXL4 LOXL3	1.25e-04	12	32	2	CID000026069
Drug	pheniprazine	LOXL4 LOXL3	1.25e-04	12	32	2	CID000005929
Drug	viloxazine	LOXL4 LOXL3	1.25e-04	12	32	2	CID000005666
Drug	kojic amine	LOXL4 LOXL3	1.25e-04	12	32	2	CID000003841
Drug	MPDP	LOXL4 LOXL3	1.25e-04	12	32	2	CID000150458
Drug	SKF 64139	LOXL4 LOXL3	1.48e-04	13	32	2	CID000123919
Drug	clozapine; Up 200; 10uM; MCF7; HG-U133A	GPR4 NXN CBFA2T2 POP1	1.68e-04	199	32	4	416_UP
Drug	Glimepiride [93479-97-1]; Down 200; 8.2uM; PC3; HT_HG-U133A	GPR4 SLC9A1 ZNF276 CBFA2T2	1.71e-04	200	32	4	6628_DN
Drug	isocarboxazid	LOXL4 LOXL3	1.72e-04	14	32	2	CID000003759
Drug	benzylhydrazine	LOXL4 LOXL3	1.72e-04	14	32	2	CID000011157
Drug	kynuramine	LOXL4 LOXL3	1.72e-04	14	32	2	CID000009692
Drug	lazabemide	LOXL4 LOXL3	1.72e-04	14	32	2	CID000071307
Drug	2'CH3-MPTP	LOXL4 LOXL3	1.72e-04	14	32	2	CID000091767
Drug	FMMT	LOXL4 LOXL3	1.72e-04	14	32	2	CID006438682
Drug	MDL 72145	LOXL4 LOXL3	1.72e-04	14	32	2	CID006438383
Drug	styrene	LOXL4 LOXL3 CA3	1.79e-04	78	32	3	CID000007501
Drug	milacemide	LOXL4 LOXL3	1.99e-04	15	32	2	CID000053568
Drug	MFMD	LOXL4 LOXL3	1.99e-04	15	32	2	CID000122302
Drug	bupropion	SCNN1D LOXL4 LOXL3	2.00e-04	81	32	3	CID000000444
Drug	Ro 41-1049	LOXL4 LOXL3	2.27e-04	16	32	2	CID000005086
Disease	primary ovarian insufficiency (implicated_via_orthology)	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	1.06e-40	46	45	18	DOID:5426 (implicated_via_orthology)
Disease	congenital heart disease (implicated_via_orthology)	USP17L7 USP17L6P USP17L3 USP17L5 USP17L21 USP17L10 USP17L19 USP17L2 USP17L12 USP17L1 USP17L22 USP17L17 USP17L20 USP17L11 USP17L15 USP17L24 USP17L13 USP17L18	6.33e-37	69	45	18	DOID:1682 (implicated_via_orthology)
Disease	L-Selectin measurement	SELL TENM1	1.03e-03	31	45	2	EFO_0008202
Disease	response to paliperidone, schizophrenia symptom severity measurement	ANO4 COL26A1 NXN	4.38e-03	216	45	3	EFO_0007925, EFO_0007927

Protein segments in the cluster

Peptide	Gene	Start	Entry
GYASHNGPDHWHELF	CA3	6	P07451
LFHYCGQHLHAARWH	ARSD	456	P51689
HGAENHRHLLYECWA	ANO4	311	Q32M45
ECQHREWGSHNCYHG	CD163L1	126	Q9NR16
IVQHHHWPFGGAACS	C5AR1	96	P21730
AGRHSWVWHECHGHY	LOXL3	596	P58215
KYDGHRIWVHNCHIG	LOXL3	716	P58215
YDGHRVWLHNCHTGN	LOXL4	721	Q96JB6
YCGSFCQHKDWERHH	CBFA2T2	526	O43439
GWHQHSGYCHILITE	FREM1	2056	Q5H8C1
LAHHGTDCWTYHYSE	SELL	31	P14151
TIHCIFHATGHHYTW	OSBP	561	P22059
YFLHHDNWIHGPGSC	GPR4	76	P46093
LHEDWHYCGPQESKH	POP1	886	Q99575
HQLSHYSLAEAWGHG	GGT5	371	P36269
CDHHSGDYKHFREWG	CRYBA4	166	P53673
LYEAHGSHVDCWLHL	MAN2C1	976	Q9NTJ4
GAEYCSSARHPAWGH	SCNN1D	581	P51172
AGHHNWIVAAYAHFA	KCTD3	191	Q9Y597
GSGYASRRHWCHHTV	COL26A1	46	Q96A83
AQRGCYTWHSTHHDA	NUP210L	61	Q5VU65
CEQWGNYFLHSGHLH	CARS2	296	Q9HA77
LEGSHVGVYFSAHWC	NXN	191	Q6DKJ4
QPWAYLSCGHVHGYH	PELI2	306	Q9HAT8
LSCGHVHGYHNWGHR	PELI2	311	Q9HAT8
GWEGDHCTIAHYLDA	TENM1	746	Q9UKZ4
AVLVHAGWSCHDGHY	USP17L3	321	A6NCW0
SDCFHLGWGQHNCGH	SSC4D	421	Q8WTU2
AVLVHAGWSCHNGHY	USP17L18	321	D6R9N7
AVLVHAGWSCHNGHY	USP17L5	321	A8MUK1
LHGLVGWVHGHAASC	ZNF276	196	Q8N554
AVLVHAGWSCHNGHY	USP17L21	321	D6R901
AVLVHAGWSCHNGHY	USP17L13	321	C9JLJ4
DICGHYGHHHWKDKL	SLC9A1	536	P19634
AVLVHAGWSCHNGHY	USP17L19	321	D6RCP7
AVLVHAGWSCHDGHY	USP17L1	321	Q7RTZ2
AVLVHAGWSCHNGHY	USP17L12	321	C9JPN9
AVLVHAGWSCHNGHY	USP17L24	321	Q0WX57
AVLVHAGWSCHNGHY	USP17L7	321	P0C7H9
TAHGVFICYWDGTVH	TM6SF2	106	Q9BZW4
AVLVHAGWSCHNGHY	USP17L6P	321	Q6QN14
AVLVHAGWSCHNGHY	USP17L22	321	D6RA61
AVLVHAGWSCHNGHY	USP17L15	321	C9J2P7
AVLVHAGWSCHNGHY	USP17L17	321	D6RBQ6
AVLVHAGWSCHDGHY	USP17L2	321	Q6R6M4
AVLVHAGWSCHNGHY	USP17L20	321	D6RJB6
AVLVHAGWSCHNGHY	USP17L10	321	C9JJH3
AVLVHAGWSCHNGHY	USP17L11	321	C9JVI0